ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

Development of an ETEC multivalent subunit vaccine using outer membrane vesicles

Active
Institution
TULANE UNIVERSITY OF LOUISIANA, LA
Principal investigator
Jacob P. Bitoun
Funding
$186K
Duration
2025–2027
Open portfolio

Moonbase score

Still being scored

Abstract

Project Summary Vaccines are one of the most important medical interventions in history, yet no vaccines exist that protect against enterotoxigenic Escherichia coli (ETEC) - one of the major diarrheagenic pathogens in children in low-resource settings. ETEC pathogenesis begins with fecal-oral dissemination, attachment to the small intestinal epithelium via colonization factors (CFs), and elaboration of the heat-labile (LT) and heat-stable (ST) enterotoxins. The majority of ETEC vaccine efforts have focused primarily on generation of protective immune responses to CFs and LT, and vaccine antigens that provide coverage to ST are a critical gap in achieving full vaccine protection. Addressing this gap is imperative since large epidemiological studies have shown that ST is associated with the most severe cases of ETEC diarrheal disease. Here we will test the central hypothesis that immunization with outer membrane vesicle (OMV)-adjuvanted multivalent vaccines can establish anti-ETEC immunity in the gastrointestinal tract, where it is needed to neutralize enterotoxins and block bacterial colonization. Our hypothesis is supported by preliminary data demonstrating that OMV-adjuvanted ST and OMV-adjuvanted CFs induce ST- and CF-specific antibodies, respectively. Studies in Aim 1 will test the hypothesis that antibodies produced following immunization with OMV-adjuvanted ST and LT toxoids will protect against toxin-mediated secretory diarrhea. Studies in Aim 2 will test the hypothesis that antibodies produced following immunization with OMV-adjuvanted CFs will prevent ETEC colonization of the small intestinal epithelium. Development of an effective multivalent vaccine against ETEC would have a major impact on public health by reducing the global burden of bacterial diarrhea.

LOADING MOONBASE SCORE

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESR21Vaccines Against Infectious Diseases Study Section[VID]immunizationdiarrheavaccinecolonizationintestinal epitheliumouter membranemultivalentcfs

Questions for TULANE UNIVERSITY OF LOUISIANA

Answered by the team behind this research.

Same institution, same topic, scored first.